Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $50

10x Genomics -0.80%

10x Genomics

TXG

19.84

-0.80%

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ: TXG) with a Buy and lowers the price target from $65 to $50.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via